Boostrix Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Boostrix market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

Market growth during the historical period can be attributed to maternal immunization programs, mandatory vaccination policies in schools, expanding healthcare infrastructure, support for booster doses, and an emphasis on post-injury vaccination.

The projected growth during the forecast period is driven by global immunization initiatives, a rising elderly population, increased awareness of preventable diseases, more government vaccination programs, and a surge in the export of generic vaccines. Key trends in the forecast period include developments in cold chain logistics, technological advancements, innovative partnerships, global collaborations, and the introduction of new products.

The growth of the boostrix market is expected to be driven by the increasing government initiatives for vaccination. Government initiatives refer to the strategies, policies, and actions taken by governments to address public health concerns, and these are rising globally due to growing awareness of the benefits of vaccination, advancements in vaccine technology, and efforts to reduce the spread of infectious diseases. Initiatives for Boostrix (Tdap vaccine) specifically aim to increase its administration to prevent tetanus, diphtheria, and pertussis (whooping cough), particularly among vulnerable populations. For example, in July 2024, the Department of Health and Social Care in the UK announced the country's pioneering national vaccination program to use the same vaccine to protect both infants and older adults against RSV. Therefore, the rise in government vaccination initiatives is fueling the growth of the boostrix market.

The growth of the boostrix market is also expected to be accelerated by the increase in clinical trials. Clinical trials are research studies involving human participants to assess the safety, efficacy, and effectiveness of medical treatments, drugs, or devices. These trials are growing due to advancements in medical research and technology, the rising prevalence of chronic and complex diseases, and the aging global population requiring new treatments. Clinical trials are particularly important for Boostrix as they provide essential data to confirm the vaccine’s safety and effectiveness in preventing pertussis, tetanus, and diphtheria across different age groups. For instance, in February 2024, ClinicalTrials.gov reported that in 2022, 4,024 clinical trials published findings, which increased to 5,063 in 2023. As a result, the rise in clinical trials is driving the growth of the boostrix market.

A key trend in the boostrix market is the adoption of innovative products, such as vaccines for maternal immunization, which offer enhanced protection for newborns against infectious diseases. Maternal immunization vaccines are designed to transfer protective antibodies from the mother to the infant, providing better protection during the early months of life. For example, in November 2024, GSK plc, a UK-based pharmaceutical company, introduced BOOSTRIX for immunization during pregnancy to prevent whooping cough (pertussis) in infants under two months. This vaccine, approved by the FDA in the US, is administered during the third trimester of pregnancy, allowing antibodies to be transferred from mother to child. Boostrix is especially impactful for safeguarding newborns who are highly vulnerable to pertussis, addressing a significant public health need.

The key company operating in the boostrix market is GSK plc.

North America was the largest region in the boostrix market in 2024. The regions covered in boostrix report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the boostrix market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Boostrix is a vaccine that provides protection against tetanus, diphtheria, and pertussis (whooping cough). It is typically used as a booster dose for adolescents and adults, following initial vaccinations received in childhood, to enhance immunity. Boostrix is commonly recommended during pregnancy to protect newborns from pertussis and in situations where individuals may be at risk of tetanus due to injuries.

The primary indications for boostrix are tetanus, diphtheria, and pertussis (whooping cough). Tetanus is a serious bacterial infection caused by toxins that affect the nervous system, often resulting from wounds contaminated with the bacteria. The vaccine is available for various age groups, including adolescents, adults, and the elderly, and is distributed through channels such as hospital pharmacies, retail pharmacies, and online pharmacies. The primary end users include hospitals, clinics, and vaccination centers.

The boostrix market research report is one of a series of new reports that provides boostrix market statistics, including boostrix industry global market size, regional shares, competitors with a boostrix market share, detailed Boostrix market segments, market trends and opportunities, and any further data you may need to thrive in the boostrix industry. This boostrix market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The boostrix market consists of sales of boostrix (Tdap) and Boostrix-IPV (Tdap-IPV). Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.